Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Chiesi Farmaceutici SpA Snapshot | 6 | 1 |
| Chiesi Farmaceutici SpA Overview | 6 | 1 |
| Key Facts | 6 | 1 |
| Chiesi Farmaceutici SpA Research and Development Overview | 7 | 3 |
| Key Therapeutic Areas | 7 | 3 |
| Chiesi Farmaceutici SpA Pipeline Review | 10 | 7 |
| Pipeline Products by Stage of Development | 10 | 1 |
| Pipeline Products Monotherapy | 11 | 1 |
| Pipeline Products Combination Treatment Modalities | 12 | 1 |
| Pipeline Products Partnered Products | 13 | 1 |
| Partnered Products/Combination Treatment Modalities | 14 | 1 |
| Pipeline Products Out-Licensed Products | 15 | 1 |
| Out-Licensed Products/Combination Treatment Modalities | 16 | 1 |
| Chiesi Farmaceutici SpA Pipeline Products Glance | 17 | 5 |
| Chiesi Farmaceutici SpA Late Stage Pipeline Products | 17 | 1 |
| Phase III Products/Combination Treatment Modalities | 17 | 1 |
| Chiesi Farmaceutici SpA Clinical Stage Pipeline Products | 18 | 1 |
| Phase II Products/Combination Treatment Modalities | 18 | 1 |
| Phase I Products/Combination Treatment Modalities | 19 | 1 |
| Chiesi Farmaceutici SpA Early Stage Pipeline Products | 20 | 1 |
| Preclinical Products/Combination Treatment Modalities | 20 | 1 |
| Chiesi Farmaceutici SpA - Unknown Stage Pipeline Products | 21 | 1 |
| Unknown Products/Combination Treatment Modalities | 21 | 1 |
| Chiesi Farmaceutici SpA Drug Profiles | 22 | 23 |
| (beclomethasone dipropionate + formoterol fumarate + glycopyrrolate) Drug Profile | 22 | 3 |
| budesonide Drug Profile | 25 | 1 |
| CHF-5633 Drug Profile | 26 | 1 |
| CHF-6001 Drug Profile | 27 | 2 |
| CHF-6297 Drug Profile | 29 | 1 |
| CPD-15 Drug Profile | 30 | 1 |
| Drugs for Bronchopulmonary Dysplasia Drug Profile | 31 | 1 |
| glycopyrrolate Drug Profile | 32 | 2 |
| melatonin Drug Profile | 34 | 1 |
| meropenem Drug Profile | 35 | 1 |
| Recombinant Enzymes for Rare Diseases Drug Profile | 36 | 1 |
| Recombinant Protein for Neonatal Respiratory Distress Syndrome Drug Profile | 37 | 1 |
| Recombinant Protein to Target NGF for Undisclosed Indication Drug Profile | 38 | 1 |
| Small Molecule to Inhibit Neutrophil Elastase for Respiratory Diseases Drug Profile | 39 | 1 |
| Small Molecule to Target Beta 2 Adrenergic Receptor and Muscarinic Acetylcholine Receptor M3 for Asthma and COPD Drug Profile | 40 | 1 |
| Small Molecules for Neonatal Abstinence Syndrome Drug Profile | 41 | 1 |
| TRP-601 Drug Profile | 42 | 1 |
| velmanase alfa Drug Profile | 43 | 2 |
| Chiesi Farmaceutici SpA Pipeline Analysis | 45 | 6 |
| Chiesi Farmaceutici SpA Pipeline Products by Target | 45 | 2 |
| Chiesi Farmaceutici SpA Pipeline Products by Route of Administration | 47 | 1 |
| Chiesi Farmaceutici SpA Pipeline Products by Molecule Type | 48 | 1 |
| Chiesi Farmaceutici SpA Pipeline Products by Mechanism of Action | 49 | 2 |
| Chiesi Farmaceutici SpA Dormant Projects | 51 | 1 |
| Chiesi Farmaceutici SpA Discontinued Pipeline Products | 52 | 2 |
| Discontinued Pipeline Product Profiles | 53 | 1 |
| beclomethasone dipropionate SR | 53 | 1 |
| carmoterol | 53 | 1 |
| indantadol | 53 | 1 |
| Porphozym | 53 | 1 |
| Chiesi Farmaceutici SpA Company Statement | 54 | 2 |
| Chiesi Farmaceutici SpA Locations And Subsidiaries | 56 | 4 |
| Head Office | 56 | 1 |
| Other Locations &Subsidiaries | 57 | 3 |
| Appendix | 60 | 2 |
| Methodology | 60 | 1 |
| Coverage | 60 | 1 |
| Secondary Research | 60 | 1 |
| Primary Research | 60 | 1 |
| Expert Panel Validation | 60 | 1 |
| Contact Us | 60 | 1 |
| Disclaimer | 61 | 1 |